Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
1004.95 €
In Stock
quantity
product details
Catalog number: 1142 - DLL-0011-2ML
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 2mL
DLL-0011-10ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
3024.95 €
DLL-0011-2ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
1004.95 €
DLL-0005-A1-10ML
Adavosertib Liposomes, Formulation WD4
PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.
5044.95 €